Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States
Sweet DE, Altice FL, Cohen CJ, Vandewalle B. Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States. PLOS ONE 2016, 11: e0147821. PMID: 26808503, PMCID: PMC4725959, DOI: 10.1371/journal.pone.0147821.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCD4 Lymphocyte CountDrug Administration ScheduleFemaleHIV InfectionsHIV-1HumansMaleMiddle AgedQuality-Adjusted Life YearsTabletsUnited StatesViral LoadConceptsSingle-tablet regimensSubstantial price reductionsTenofovir disoproxil fumarate/emtricitabineCost-effectiveness thresholdIncremental cost-effectiveness ratioGeneric medicationsDaily single-tablet regimensDisoproxil fumarate/emtricitabineCost-effectiveness ratioElvitegravir/cobicistatCombination antiretroviral therapyHIV-1 patientsSingle-tablet regimenHigher inpatient costsHIV-1 infectionIncremental lifetime costPrice reductionEconomic outcomesMicrosimulation modelSuch policiesGeneric lamivudineTablet regimensAntiretroviral therapyU.S. settingsComplex regimens